MedTrace Logo

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

NCT00383045 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-03-31

No results posted yet for this study

Summary

A randomized clinical trial comparing drug abuse and HIV risk reduction counseling (DC-HIV) alone, DC-HIV combined with naltrexone maintenance, and DC-HIV combined with buprenorphine maintenance for the treatment of heroin addicts in Malaysia.

Conditions

  • Opiate Dependence

Interventions

DRUG

Buprenorphine/Subutex

DRUG

Naltrexone

PROCEDURE

Drug counseling

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Richard S. Schottenfeld, M.D. · Yale University

  • Mahmud Mazlan, M.D. · Hospital Muar, Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Completion
2007-08-31

Countries

  • United States
  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383045 on ClinicalTrials.gov